BioCentury
ARTICLE | Company News

FDA adds warning to HCV drugs' labels

October 4, 2016 7:00 AM UTC

On Tuesday, FDA added a boxed warning to the labels of direct-acting antivirals for HCV. The warning describes the risk of reactivation of HBV infection in patients receiving the therapies.

The agency said healthcare providers should screen all patients for current or prior HBV infection before starting therapy. ...